UNSPSC 51142522: Dihydroergocryptine

This classification denotes an antiparkinson drug with the molecular formula C32H43N5O5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 67V3FSL2GL, chemically known as ergotaman-3',6',18-trione, 9,10-dihydro-12'-hydroxy-2'-(1-methylethyl)-5'-(2-methylpropyl)-, but generally known as Dihydroergocryptine, which bears US NIH Compound Identifier 114948. European Medicines Agency schedules Dihydroergocryptine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB13588MIG.

World Health Organization schedules amantadine in its Anatomical Therapeutic Chemical (ATC) Classification. As of Q4 2014, DIHYDROERGOCRYPTINE remains the US FDA Preferred Term for this commodity. SMILES: CC(C)CC1C(=O)N2CCCC2C3(N1C(=O)C(O3)(C(C)C)NC(=O)C4CC5C(CC6=CNC7=CC=CC5=C67)N(C4)C)O.

UNSPSC 51142522 Dihydroergocryptine is a Commodity code that nominally covers a specific pharmaceutical compound, but the recent state and local procurement activity indexed under this code shows minimal alignment with its abstract scope. Seminole County, Florida posted an IFB in June 2026 for Naloxone and Safe Drug Deactivation Systems — opioid-reversal medication and drug disposal equipment — which bears no clear relationship to dihydroergocryptine, a dopamine agonist used in ergot-derived treatments. The mismatch suggests either a coding error in the source index or a jurisdictional tagging practice that does not reflect the code's intended commodity scope. State and local procurement databases sometimes apply broader or adjacent codes when exact matches are unavailable, or when purchasing systems default to a general pharmaceutical tier rather than drilling to the specific active ingredient.

The Seminole County opportunity represents the only recent state and local activity appearing under this code in the source material. The county sought 1,900 units of Naloxone and 800 Safe Drug Deactivation Systems annually through an IFB posted June 30, 2026, with a response deadline of July 26, 2026, at 2:00 pm. Quarterly deliveries were required to the Seminole County Community Health Building in Sanford, Florida, with vendors responsible for all shipping and delivery costs. The contract carried a two-year initial term with a one-year renewal option, required E-Verify compliance and drug-free workplace certification, and involved potential FEMA funding with attendant federal compliance obligations. The code shows little recent relevant activity for dihydroergocryptine procurement; business development professionals should verify the correct commodity or family code before developing pursuit strategy under this classification.